High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement

计划入组 40 人 · 首次发布于 2008 年 12 月 3 日

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas

计划入组 20 人 · 首次发布于 2014 年 9 月 25 日

Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas

计划入组 13 人 · 首次发布于 2016 年 9 月 7 日

dual anti-CD19/anti-CD20 CAR T-cells (chronic lymphocytic leukemia/B-cell lymphomas)

Lisocabtagene maraleucel(Breyanzi)

Axicabtagene ciloleucel(Yescarta)

Rx

AB&B BIO-TECH-B

Gamida Cell

Israel

GAMIDA CELL INC.

United States

Roche's Glofitamab Expands Treatment Horizons for Multiple B-Cell Lymphomas

FDA Approves Two Bispecific T-Cell Engagers for Relapsed/Refractory B-Cell Lymphomas

Subcutaneous Mosunetuzumab Shows Promise in Untreated B-Cell Lymphomas with Durable Responses